Pathology & Oncology Research

, 17:859

Identification of PEG10 and TSG101 as Carcinogenesis, Progression, and Poor-Prognosis Related Biomarkers for Gallbladder Adenocarcinoma

Research

Abstract

PEG10 is a transcriptional factor while TSG101 is involved in numerous cellular processes, including apoptotic resistance. Overexpression of PEG10 and TSG101 were observed in a variety of human cancers. However, their expression and clinical significance in gallbladder cancer (GBC) have not yet been identified. To understand the tumor biology of GBC at the molecular level, we examined PEG10 and TSG101 expression in 108 adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues by using immunohistochemistry. Overexpression of PEG10 and TSG101 was detected in gallbladder adenocarcinoma (48.1% and 47.2%, respectively). Conversely, there was less expression detected in the peritumoral tissues (19.6%), adenomatous polyps (13.3%), and gallbladder epithelium with chronic cholecystitis (5.1%) (p < 0.01, p < 0.05, and p < 0.01, respectively). Notably, the benign lesions with positive PEG10 and/or TSG101 expression showed moderately or severely atypical hyperplasia in gallbladder epithelium. The overexpression of PEG10 and TSG101 was significantly associated with differentiation, tumor mass, lymph node metastasis and invasion of adenocarcinoma. Univariate Kaplan-Meier analysis showed that overexpression of PEG10 (p = 0.041) and TSG101 (p = 0.025) was closely associated with decreased overall survival. Multivariate Cox regression analysis revealed that positive expression of PEG10 (p = 0.036) or TSG101 (p = 0.022) is a predictor of poor prognosis in gallbladder adenocarcinoma. Our study suggested that overexpression of PEG10 and TSG101 might be closely related to the carcinogenesis, progression, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma.

Keywords

Gallbladder cancer Gallbladder polyp Chronic cholecystitis PEG10 TSG101 

References

  1. 1.
    Ono R, Kobayashi S, Wagatsuma H et al (2001) A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73:232–237PubMedCrossRefGoogle Scholar
  2. 2.
    Okabe H, Satoh S, Furukawa Y et al (2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63:3043–3048PubMedGoogle Scholar
  3. 3.
    Kainz B, Shehata M, Bilban M et al (2007) Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 121:1984–1993PubMedCrossRefGoogle Scholar
  4. 4.
    Tsuji K, Yasui K, Gen Y et al (2010) PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 198:118–125PubMedCrossRefGoogle Scholar
  5. 5.
    Chunsong H, Yuling H, Li W et al (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23 + CD5+ B cells. J Immunol 177:6713–6722PubMedGoogle Scholar
  6. 6.
    Li CM, Margolin AA, Salas M et al (2006) PEG10 is a c-MYC target gene in cancer cells. Cancer Res 66:665–672PubMedCrossRefGoogle Scholar
  7. 7.
    Ip WK, Lai PB, Wong NL et al (2007) Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250:284–91PubMedCrossRefGoogle Scholar
  8. 8.
    Jie X, Lang C, Jian Q et al (2007) Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26:5741–5751PubMedCrossRefGoogle Scholar
  9. 9.
    Lux A, Beil C, Majety M et al (2005) Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. J Biol Chem 280:8482–8493PubMedCrossRefGoogle Scholar
  10. 10.
    Ono R, Nakamura K, Inoue K et al (2006) Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet 38:101–106PubMedCrossRefGoogle Scholar
  11. 11.
    Liu RT, Huang CC, You HL et al (2002) Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21:4830–4837PubMedCrossRefGoogle Scholar
  12. 12.
    Young TW, Rosen DG, Mei FC et al (2007) Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res 13:3848–3854PubMedCrossRefGoogle Scholar
  13. 13.
    Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235–240PubMedCrossRefGoogle Scholar
  14. 14.
    Ma XR, Edmund Sim UH, Pauline B et al (2008) Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop Biomed 25:46–57PubMedGoogle Scholar
  15. 15.
    Li L, Liao J, Ruland J et al (2001) A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci USA 98:1619–1624PubMedCrossRefGoogle Scholar
  16. 16.
    Li L, Cohen SN (1996) Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319–329PubMedCrossRefGoogle Scholar
  17. 17.
    Zhu G, Gilchrist R, Borley N et al (2004) Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109:541–547PubMedCrossRefGoogle Scholar
  18. 18.
    Bashirova AA, Bleiber G, Qi Y et al (2006) Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 80:6757–6763PubMedCrossRefGoogle Scholar
  19. 19.
    Goldin RD, Roa JC (2009) Gallbladder cancer: a morphological and molecular update. Histopathology 55:218–229PubMedCrossRefGoogle Scholar
  20. 20.
    Gatto M, Bragazzi MC, Semeraro R et al (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253–260PubMedCrossRefGoogle Scholar
  21. 21.
    Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331–342PubMedCrossRefGoogle Scholar
  22. 22.
    Maurya SK, Tewari M, Mishra RR (2010) Genetic abberations in gallbladder cancer. Surg Oncol Sep 28. [Epub ahead of print]Google Scholar
  23. 23.
    Sanada Y, Yoshida K, Ohara M, Tsutani Y (2007) Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 13:105–113PubMedCrossRefGoogle Scholar
  24. 24.
    Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326–335PubMedCrossRefGoogle Scholar
  25. 25.
    Németh Z, Szász AM, Somorácz A, Tátrai P, Németh J et al (2009) Zonula Occludens-1, Occludin, and E-cadherin Protein Expression in Biliary Tract cancers. Pathol Oncol Res 15:533–539PubMedCrossRefGoogle Scholar
  26. 26.
    Li Q, Yang Z (2009) Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp& Clin Cancer Res 28:65–72CrossRefGoogle Scholar
  27. 27.
    Li Q, Yang Z, Liu J, et al (2010). Expression of CDx2 and Hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic typr and clinical outcome. Pathol Oncol Res Dec 28. 2010 [Epub ahead of print]Google Scholar
  28. 28.
    Malik IA (2004) Gallbladder cancer: current status. Expert Opin Pharmacother 5:1271–1277PubMedCrossRefGoogle Scholar
  29. 29.
    Tucek S, Tomasek J, Halámkova J (2010) Bile duct malignancies. Klin Onkol 23:231–241PubMedGoogle Scholar
  30. 30.
    Zhao Y, You H, Liu F et al (2002) Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 185:211–218PubMedCrossRefGoogle Scholar
  31. 31.
    Shen H, Pan Y, Han Z et al (2004) Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther 3:561–565PubMedGoogle Scholar
  32. 32.
    Lee CT, Park KH, Yanagisawa K et al (2004) Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 64:6660–6665PubMedCrossRefGoogle Scholar
  33. 33.
    Lee CT, Lee YJ, Kwon SY et al (2006) In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27. Cancer Res 66:372–377PubMedCrossRefGoogle Scholar
  34. 34.
    Huang Q, Zhang X, Wang H et al (2004) A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10:1439–1445PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2011

Authors and Affiliations

  1. 1.Department of Geriatric SurgeryCentral South UniversityHunanChina
  2. 2.Research Laboratory of Hepatobiliary Diseases, Second Xiangya HospitalCentral South UniversityHunanChina

Personalised recommendations